Lantheus shares trade under the ticker LNTH. Curium is the acquirer, and Lantheus is the target.
At closing, each Lantheus share will be converted into $102.50 in cash. Investors could also receive as much as $12 per share, contingent on Lantheus achieving specified sales milestones by 2030. At the maximum, each share is valued at $114.50, a roughly 14.9% premium over Lantheus' last closing price of $99.64.
This setup provides shareholders with a guaranteed cash sum at closing plus a performance-based opportunity for more money later. If Lantheus' sales reach the agreed milestones before the end of 2030, the total payout rises toward the upper end of the range. The companies said the maximum value of the deal is about $8 billion.
If Lantheus misses the targets, the deal could still close at the $102.50 per share cash price. The exact amount of the extra payment, if any, is tied to the actual sales results over that period. That fixed payment gives shareholders a known floor, while the additional payment depends on how Lantheus performs against the targets through 2030. The guaranteed cash portion alone is about 2.9% above Lantheus' last close, while the maximum possible payout represents a 14.9% premium.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
The final total will be determined by Lantheus' sales performance between now and 2030. If the milestones are not reached, shareholders would receive only the guaranteed cash payment, and the deal's total value would fall below $8 billion. If the milestones are met, the total payout moves toward the maximum.
The transaction combines a fixed cash payment with a contingent earn-out. If Lantheus meets the sales milestones, the per-share value climbs to $114.50 and the aggregate deal value approaches $8 billion. If it misses them, shareholders still have the $102.50 floor, but the total consideration would stay below the maximum. This arrangement shifts some of the risk of future sales performance to shareholders while rewarding them if Lantheus meets its targets.
Lantheus operates in the radiopharmaceutical field. Radiopharmaceuticals are used across medicine for diagnostic and therapeutic purposes, and Lantheus' history in that area goes back more than seven decades, according to its CEO. The transaction would make Lantheus a part of Curium, the buyer, following the close.
The deal would bring Lantheus' long-running radiopharmaceutical business under Curium's ownership. By acquiring Lantheus, Curium would add a business with a long track record in both diagnostic and therapeutic radiopharmaceuticals.
Radiopharmaceuticals work by carrying a radioactive substance to specific cells, which lets doctors see disease through imaging or deliver treatment directly to unhealthy tissue. Lantheus has built its business in this field over seven decades, and combining that expertise with Curium would create a broader radiopharmaceutical company.
Mary Anne Heino, Lantheus' CEO, said, "We believe this transaction is the ultimate validation of what the Lantheus team has built over seven decades of innovation in radiopharmaceuticals."
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
